Caribou Biosciences Inc. (CRBU)
NASDAQ: CRBUHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRBU stock chart
Technical analysisKey statistics
All statistics- Market cap
- $30.71M
- EPS (TTM)
- -$1.03
- Dividend yield
- None
- 52-week range
- 0.2819 – 2.49
- Day range
- 0.2819 – 0.3051
- Volume / Avg
- 3.26M / 2.87M
- Beta
- —
- Shares outstanding
- 108.04M
52-week range
CRBU stock today
On Nov 20, CRBU ended the session at $0.2843, shedding $0.0262 (8.44%), versus the S&P 500's 3.70% decline. At this level, CRBU sits near the bottom of its 52-week range of $0.2819 to $2.49: 88.6% below the high, set on Jun 1, 2026 and 0.9% above the low. CRBU is down 82.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.8%.
Caribou Biosciences has posted a net loss over the last twelve months (EPS of -$1.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Caribou Biosciences
Company profileCaribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Rachel E. Haurwitz Ph.D.
- Headquarters
- Berkeley, CA
- Employees
- 97
- IPO year
- 2021
- Website
- cariboubio.com
Financial highlights
Full financialsIn fiscal 2025, Caribou Biosciences generated $11.2 million in revenue, up 11.7% from fiscal 2024. Caribou Biosciences reported a net loss of $148.1 million, compared with a loss of $149.1 million a year earlier. Operating margin was -1329.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $11.16M | $9.99M | $34.48M | $13.85M | $9.60M |
| Growth | +11.66% | -71.01% | +148.91% | +44.31% | -22.35% |
| Net income | $-148.13M | $-149.10M | $-102.07M | $-99.42M | $-66.92M |
| EPS (diluted) | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$5.75+1922.51%
- Strong buy 0
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.25 vs $-0.27
- Surprise
- +7.41%
CRBU news
All CRBU news- Petrobras to Report Q3 Earnings: What's in the Cards for the Stock?NasdaqPBR, AZ, ITRG, CRBU
- Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?NasdaqA, TGTX, CRBU, AARD
- Caribou Biosciences, Inc. (CRBU) Expected to Beat Earnings Estimates: Can the Stock Move Higher?NasdaqCRBU, MRNA
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial DataNasdaqABBV, ALVO, ARGX, BBIO
- Thursday Sector Laggards: Biotechnology, Packaging & ContainersNasdaqCRBU, RXRX, ORBS, PACK
- Here's Why You Should Retain IQVIA Stock in Your Portfolio NowNasdaqIQV, GMED, CRBU
Caribou Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KLRSKalaris Therapeutics Inc. | 1.28 | -5.19% | $30.47M | vs CRBU |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs CRBU |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs CRBU |
| TILInstil Bio Inc. | 5.23 | -5.77% | $35.47M | vs CRBU |
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs CRBU |
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs CRBU |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs CRBU |
| ELUTElutia Inc. Class A | 0.9001 | +11.12% | $39.96M | vs CRBU |
Indexes, lists and sector
Caribou Biosciences stock FAQ
What is Caribou Biosciences's stock price today?
CRBU last traded at $0.2843 as of Nov 20, 4:00 PM EST, down 8.44% on the day. Prices are delayed at least 15 minutes.
Who is Caribou Biosciences's CEO?
Dr. Rachel E. Haurwitz Ph.D. is the chief executive officer of Caribou Biosciences Inc., which has about 97 employees.
What is the CRBU 52-week high?
The 52-week high for CRBU is $2.49 and the 52-week low is $0.2819. The stock is currently 88.6% below its high.